Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Adverse Events / Safety & Irinotecan

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

The severity of irinotecan-induced GI toxicity varies considerably between patients and may be due to the interindividual variability of the human gut microbiota.
Kweekel et al. 2008 Cancer Treat. Rev 34: 656-669
Guthrie et al. 2017 NPJ Biofilms Microbiomes 3: 27

…

References (Sources)

Alleviating cancer drug toxicity by inhibiting a bacterial enzyme
Wallace et al. 2010 Science 330: 831–835
Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat.
Stringer et al. 2007 Exp Biol Med 232: 96-106
Clinical and pharmacogenetic factors associated with irinotecan toxicity
Kweekel et al. 2008 Cancer Treat. Rev 34: 656-669
Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats
Stringer et al. 2008 Cancer Biol Ther. 7: 1919-25
Human microbiome signatures of differential colorectal cancer drug metabolism
Guthrie et al. 2017 NPJ Biofilms Microbiomes 3: 27
Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
Takasuna et al. 1996 Cancer Res 56: 3752-7

AI Chat

5/30/2026

Chat with our artificial intelligence:

Start chat!

Adverse Events / Safety & Irinotecan

Welcome to meRfi-GM!

Navigation

Contents

References (Sources)

AI Chat